AVI Polymers Limited has filed a business update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, dated May 06, 2026, announcing exceptional early traction for its HealthTech AI platform, Ashwini Healthcare AI, available at www.ashwini.tech . The company reports a highly engaged waitlist of over 5,620 registered users since the platform's soft launch, which it states validates its strategic pivot into scalable digital platforms.

Platform Overview and Early Adoption

Ashwini Healthcare AI has been built on a Software-as-a-Service (SaaS) architecture. According to the company's disclosure, the organic traction witnessed since launch has been described as remarkable, with the waitlist of 5,620 users cited as strong validation of the platform's market fit. The company has invited stakeholders to view the platform live at its official portal, www.ashwini.tech .

SaaS Unit Economics and Year-1 Revenue Projections

The company has outlined its monetization model based on an annual recurring revenue structure. The following table summarises the key SaaS metrics and near-term revenue projections disclosed by the company:

The platform operates on an annual subscription priced at ₹999/year, designed for penetration in the domestic retail market. Applying industry-standard health and wellness SaaS conversion metrics of 8% to 15% to the current waitlist, the company projects an initial cohort of 600 to 900 active paying subscribers, establishing a baseline Year-1 ARR of approximately ₹6.00 Lakhs to ₹9.00 Lakhs. The platform's internal operational target is to achieve and maintain an annual retention rate of 65% to 70%.

Tiered Growth Milestones Toward ₹1 Crore ARR

The company has outlined a phased growth roadmap with specific subscriber and revenue targets. The key milestones are detailed below:

• Phase 1 targets scaling the active user base to approximately 10,000 paying subscribers, which the company states will unlock a ₹1 Crore ARR run-rate and position Ashwini Healthcare AI among top-performing early-stage SaaS platforms in the Indian market.
• Phase 2 targets an expansion of the ecosystem to 80,000 – 1,20,000 paying subscribers, with a corresponding ARR target of ₹8 Crore to ₹12 Crore, which the company describes as representative of standard Series-A valuation metrics.

Disclosure Context

The business update was filed by Managing Director Chintan Yashwantbhai Patel (DIN: 10774473) on May 06, 2026, under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The company has requested BSE Limited to place the update on record and disseminate it for the information of investors and the general public. AVI Polymers Limited is headquartered at Shop No. 02, 5th Floor, Roshpa Tower, Main Road Ranchi, Jharkhand, with its corporate office in Anand, Gujarat.

AVI Polymers Limited has officially launched its flagship personal healthcare AI platform, Ashwini.tech (AVI Health AI), completing the foundational build-out of its dual-engine AI strategy. The announcement was made on April 30, 2026, under Regulation 30 of the SEBI (LODR) Regulations, 2015, with the platform now live and operational at ashwini.tech. This launch comes ahead of the previously targeted May 3, 2026, date and follows the company's exceptional FY26 financial performance.

Official Regulatory Announcement

The Board of Directors announced that the flagship personal-healthcare AI platform is now officially live and operational, developed by wholly-owned tech subsidiary AVI Health AI. The platform brings a paradigm shift to India's digital healthcare ecosystem, engineered specifically for India's mobile-first generation. The successful launch ahead of schedule completes the dual-tech ecosystem alongside the already live and scaling KrishiBuddy agritech platform, positioning AVI Polymers at the intersection of India's fastest-growing digital markets: AgriTech and HealthTech.

FY26 Financial Performance

The company's audited financial results for the year ended March 31, 2026, demonstrate a complete business transformation. Revenue from operations expanded dramatically to ₹312.11 crore from ₹0.06 crore in FY25, while net profit after tax increased 24.9 times to ₹20.33 crore compared to ₹0.82 crore in the previous fiscal year. The company successfully completed a ₹89.99 crore rights issue during FY26, which was fully subscribed by shareholders, strengthening its balance sheet with net worth of ₹115.99 crore and cash and cash equivalents of ₹16.60 crore.

Comprehensive Platform Capabilities

Developed by wholly-owned subsidiary AVI AI Technologies Private Limited, Ashwini.tech is engineered specifically for India's mobile-first generation. The platform features six integrated instruments including The Reader for OCR and clinical extraction, The Timeline for source-linked medical history, Explain My Lab for plain-English explanations, Medication Brain for adherence tracking, Doctor Pack for printable visit summaries, and The Household for family profiles with role-aware caregiver access. The platform is currently live in private beta with conversational AI capabilities powered by Llama on Groq, providing sub-second responses with verifiable citations.

Strategic Market Positioning

Ashwini.tech operates in the Personal Health Records (PHR) segment, positioned in the high stickiness, low competition quadrant of the market landscape. The platform leverages three key tailwinds: the Ayushman Bharat Digital Mission with 670 million+ ABHA accounts and 420 million+ records linked, 825 million+ internet users with sub-₹0.20/GB data costs, and the demographic opportunity of the sandwich generation aged 35-55 managing both parents and children. The company's zero-debt balance sheet and recent capital infusion provide flexibility for commercialization and ecosystem monetization in FY27.

Multi-Engine Revenue Strategy

The platform operates on a comprehensive revenue model with consumer subscriptions planned for general availability launch, NRI premium caregiving services targeting the diaspora market within 6-12 months, Doctor Pack channels for hospital and clinic OPD partnerships in Year 2, insurance white-label solutions and ABDM gateway services in Years 2-3, and pharma real-world evidence cohorts from Year 3 onwards. The same data layer feeds each revenue engine, enabling incremental revenue without incremental cost. The company maintains a risk-conscious design with a "no diagnosis, ever" pact, ensuring the platform serves as an information aid rather than clinical decision support.